Ixazomib
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to decrease the exposure
toixazomib. Avoid.rStudy
▶Enzalutamideis predicted to decrease the exposure to
ixazomib. Avoid.rStudy
▶Mitotaneis predicted to decrease the exposure toixazomib.
Avoid.rStudy
▶Rifampicinis predicted to decrease the exposure toixazomib.
Avoid.rStudy
▶St John’s Wortis predicted to decrease the exposure to
ixazomib. Avoid.rTheoretical
Ixekizumab→see monoclonal antibodies
Kaolin
▶Kaolinis predicted to decrease the absorption oftetracyclines.
oTheoretical
Ketamine→seeTABLE 8p. 848 (hypotension),TABLE 11p. 849 (CNS
depressant effects)
▶Memantineis predicted to increase the risk of CNS side-effects
when given withketamine. Avoid.rTheoretical
Ketoconazole→see antifungals, azoles
Ketoprofen→see NSAIDs
Ketorolac→see NSAIDs
Ketotifen→see antihistamines, sedating
Labetalol→see beta blockers, non-selective
Lacidipine→see calcium channel blockers
Lacosamide→see antiepileptics
Lamivudine→seeTABLE 12p. 850 (peripheral neuropathy)
▶Trimethoprimslightly increases the exposure tolamivudine.
oStudy
Lamotrigine→see antiepileptics
Lanreotide
▶Beta blockers, non-selectiveare predicted to increase the risk
of bradycardia when given withlanreotide.oTheoretical
▶Beta blockers, selectiveare predicted to increase the risk of
bradycardia when given withlanreotide.oTheoretical
▶Lanreotideis predicted to decrease the absorption of oral
ciclosporin. Adjust dose.rTheoretical
Lansoprazole→see proton pump inhibitors
Lanthanum
▶Lanthanumis predicted to decrease the absorption of
antifungals, azoles(ketoconazole). Separate administration by
at least 2 hours.oTheoretical
▶Lanthanumis predicted to decrease the absorption of
antimalarials(chloroquine). Separate administration by at least
2 hours.oTheoretical
▶Lanthanumis predicted to decrease the absorption of
hydroxychloroquine. Separate administration by at least
2 hours.oTheoretical
▶Lanthanummoderately decreases the exposure toquinolones.
Quinolonesshould be taken 2 hours before or 4 hours after
lanthanum.oStudy
▶Lanthanumis predicted to decrease the absorption of
tetracyclines. Separate administration by 2 hours.o
Theoretical
▶Lanthanumdecreases the absorption ofthyroid hormones.
Separate administration by 2 hours.oStudy
Lapatinib→seeTABLE 9p. 849 (QT-interval prolongation)
▶Lapatinibis predicted to increase the exposure toafatinib.
Separate administration by 12 hours.oStudy
▶Lapatinibis predicted to increase the exposure toaliskiren.
oTheoretical
▶Antacidsare predicted to decrease the absorption oflapatinib.
Avoid.oTheoretical
▶Antiarrhythmics(dronedarone)are predicted to increase the
exposure tolapatinib.oStudy→Also seeTABLE 9p. 849
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to decrease the exposure
tolapatinib. Avoid.rStudy
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure tolapatinib.o
Study→Also seeTABLE 9p. 849
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure tolapatinib. Avoid.
oStudy→Also seeTABLE 9p. 849▶Lapatinibis predicted to increase the exposure to
antihistamines, non-sedating(fexofenadine).oTheoretical
▶Aprepitantis predicted to increase the exposure tolapatinib.
oStudy
▶Lapatinibis predicted to increase the exposure tobeta blockers,
non-selective(nadolol).oStudy
▶Bosentanis predicted to decrease the exposure tolapatinib.
Avoid.rStudy
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tolapatinib.oStudy
▶Lapatinibis predicted to increase the exposure toceritinib.
oTheoretical→Also seeTABLE 9p. 849
▶Cobicistatis predicted to increase the exposure tolapatinib.
Avoid.oStudy
▶Lapatinibis predicted to increase the exposure tocolchicine.
Avoid or adjustcolchicinedose.oTheoretical
▶Lapatinibis predicted to increase the risk of bleeding events
when given withcoumarins.rTheoretical
▶Crizotinibis predicted to increase the exposure tolapatinib.
oStudy→Also seeTABLE 9p. 849
▶Lapatinibis predicted to increase the exposure todabigatran.
rTheoretical
▶Lapatinibis predicted to increase the exposure todigoxin.
oTheoretical
▶Lapatinibis predicted to slightly increase the exposure to
edoxaban.rTheoretical
▶Efavirenzis predicted to decrease the exposure tolapatinib.
Avoid.rStudy→Also seeTABLE 9p. 849
▶Enzalutamideis predicted to decrease the exposure to
lapatinib. Avoid.rStudy
▶Lapatinibis predicted to increase the exposure toerlotinib.
oTheoretical
▶Lapatinibis predicted to increase the exposure toeverolimus.
oTheoretical
▶Lapatinibis predicted to increase the exposure tofidaxomicin.
Avoid.oStudy
▶Grapefruit juiceis predicted to increase the exposure to
lapatinib. Avoid.oTheoretical
▶H 2 receptor antagonistsare predicted to decrease the
absorption oflapatinib. Avoid.oTheoretical
▶HIV-protease inhibitorsare predicted to increase the exposure
tolapatinib. Avoid.oStudy→Also seeTABLE 9p. 849
▶Idelalisibis predicted to increase the exposure tolapatinib.
Avoid.oStudy
▶Imatinibis predicted to increase the exposure tolapatinib.
oStudy
▶Lapatinibis predicted to increase the exposure tolomitapide.
Separate administration by 12 hours.oTheoretical
▶Lapatinibis predicted to increase the exposure toloperamide.
oTheoretical
▶Macrolides(clarithromycin)are predicted to increase the
exposure tolapatinib. Avoid.oStudy→Also seeTABLE 9
p. 849
▶Macrolides(erythromycin)are predicted to increase the
exposure tolapatinib.oStudy→Also seeTABLE 9p. 849
▶Mitotaneis predicted to decrease the exposure tolapatinib.
Avoid.rStudy
▶Netupitantis predicted to increase the exposure tolapatinib.
oStudy
▶Nevirapineis predicted to decrease the exposure tolapatinib.
Avoid.rStudy
▶Nilotinibis predicted to increase the exposure tolapatinib.
oStudy→Also seeTABLE 9p. 849
▶Lapatinibis predicted to increase the exposure tonintedanib.
oStudy
▶Lapatinibis predicted to increase the exposure to
panobinostat. Adjust dose.oTheoretical→Also see
TABLE 9p. 849
▶Lapatinibis predicted to increase the risk of bleeding events
when given withphenindione.rTheoretical
▶Rifampicinis predicted to decrease the exposure tolapatinib.
Avoid.rStudy
▶Lapatinibis predicted to increase the exposure tosirolimus.
oTheoretical940 Ixazomib—Lapatinib BNFC 2018 – 2019
Interactions|Appendix 1A1